Fresenius Biotech GmbH is a company of the Fresenius health care group, focused on the development and marketing of biopharmaceuticals in the fields of oncology and immunology/transplantation medicine. The company also holds a majority interest in the European Institute for Research and Development of Transplantation Strategies (EUFETS AG).
The business activities of Fresenius Biotech are:
- Immunosuppression in organ transplantation
- Development of trifunctional antibodies for cancer treatment
- Manufacturing of products for cell and gene therapy (EUFETS)
Immunosuppression in organ transplantation
Fresenius Biotech is manufacturing and commercializing an immunosuppressive agent, a polyclonal antibody that is used in organ transplantation. This medicinal product has been proven to be effective in suppressing the rejection of organs by the immune system. Currently, the efficacy and safety of this immunosuppressant are being assessed in clinical trials for bone marrow transplantation and stem cell transplantation.
Development of trifunctional antibodies for cancer treatment
This innovative therapy with trifunctional antibodies activates the immune system to destroy tumor cells. Currently, clinical studies are investigating the antibodies for use against various tumors. Possible therapeutic options for future applications of the antibodies could be an adjuvant setting (after surgical resection of a tumor) or as additional immune therapy after previous chemo- or radiation therapy. Fresenius Biotech has successfully completed several clinical studies. Trifunctional antibodies are a development of our partner TRION Pharma.
Clinical Studies with Trifunctional Antibodies (PDF, 54 KB)
Manufacturing of products for cell and gene therapy
The European Institute for Research and Development of Transplantation Strategies (EUFETS AG) is a competence center for gene and cell therapy where Fresenius holds a majority interest. EUFETS can offer a comprehensive know how for the development and production of cell therapeutics, retroviral vectors and the genetic modification of primary cells or cell lines. The services include a broad spectrum ranging from process development and validation up to the production of material for clinical trials as well as for the market. In addition, EUFETS can provide cell-based in vitro safety and efficacy studies under GLP conditions as well as support of clinical studies.
Company Profile (PDF, 318 KB)
Capital Market Day Presentations, 15.1.2004
Glossary (PDF, 116 KB)